Neurocrine Biosciences, Inc.
LSE: 0K6R.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Kyle W. Gano
- Employees
- 1,800
- Headquarters
- San Diego, United States
- IPO year
- 2018
- Market cap
- $15.4B
- Website
- https://www.neurocrine.com
Loading 0K6R…
Loading profile data…Frequently asked questions about 0K6R
What does Neurocrine Biosciences, Inc. (0K6R.L) do?
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA,...
Where does 0K6R.L trade?
Neurocrine Biosciences, Inc. (0K6R.L) trades on the London Stock Exchange.
What sector is 0K6R.L in?
Neurocrine Biosciences, Inc. (0K6R.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Neurocrine Biosciences, Inc.?
Kyle W. Gano is the chief executive officer of Neurocrine Biosciences, Inc. (0K6R.L).
Where is Neurocrine Biosciences, Inc. headquartered?
Neurocrine Biosciences, Inc. is headquartered in United States.
Does 0K6R.L pay a dividend?
Neurocrine Biosciences, Inc. (0K6R.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0K6R.L go public?
Neurocrine Biosciences, Inc. (0K6R.L) completed its initial public offering in 2018.